{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:07:36Z","timestamp":1790086056080,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    SeaLAND (ALLG MM23, ACTRN12620000291987) was a randomized, open\u2010label phase III study evaluating low\u2010dose weekly selinexor (40\u2009mg) plus lenalidomide (selinexor\u2010R) versus lenalidomide alone (R) as post\u2010transplant maintenance therapy for newly diagnosed, transplant\u2010eligible multiple myeloma. A total of 142 patients were enrolled (R\u2009=\u200964; selinexor\u2010R\u2009=\u200978); the trial closed early for futility. At best response, the complete response (\u2265CR) rate was numerically, but not significantly, higher with selinexor\u2010R than R (67% vs. 53%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.09). At 24\u2009months median follow\u2010up, progression\u2010free survival (PFS) was not significantly different between selinexor\u2010R compared to R (hazard ratio [HR]\u2009=\u20091.22; 95% confidence interval [CI] 0.62\u20132.41;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.56); 24\u2010month PFS rates were 73% (95% CI 57%\u201384%) for R and 70% (95% CI: 56%\u201381%) for selinexor\u2010R. The mean relative dose intensity (RDI) of R was lower in the selinexor\u2010R arm compared to R alone (68% vs. 81%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002); the mean RDI of S was 55%. Grade \u22653 adverse events were more frequent with selinexor\u2010R (85% vs. 45%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Common severe non\u2010haematological adverse events included infections (R: 6%, selinexor\u2010R: 19%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) and gastrointestinal disorders (R: 3%, selinexor\u2010R: 14%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Selinexor\u2010R maintenance did not improve PFS and substantially increased toxicity. Selinexor\u2010R maintenance cannot be recommended for the general myeloma population; we did not observe a benefit among high\u2010risk disease.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70851","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:47:28Z","timestamp":1790084848000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3\n                    <scp>ALLG MM23<\/scp>\n                    (\n                    <scp>SeaLAND<\/scp>\n                    ) trial"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-2952","authenticated-orcid":false,"given":"Matthew J.","family":"Rees","sequence":"first","affiliation":[{"name":"Department of Haematology St Vincent's Hospital Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-4003","authenticated-orcid":false,"given":"Masa","family":"Lasica","sequence":"additional","affiliation":[{"name":"Department of Haematology St Vincent's Hospital Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-450X","authenticated-orcid":false,"given":"Anna","family":"Kalff","sequence":"additional","affiliation":[{"name":"Malignant Haematology and Stem Cell Transplantation Services Alfred Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Low","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Monash Medical Centre  Melbourne Victoria Australia"},{"name":"Monash Haematology Monash University, Clayton University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-2791","authenticated-orcid":false,"given":"Rosemary","family":"Harrup","sequence":"additional","affiliation":[{"name":"Cancer and Blood Services Royal Hobart Hospital  Hobart Tasmania Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7008-6850","authenticated-orcid":false,"given":"Hock Choong","family":"Lai","sequence":"additional","affiliation":[{"name":"Townsville Cancer Centre Townsville Hospital  Townsville Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9595-9258","authenticated-orcid":false,"given":"M. Hasib","family":"Sidiqi","sequence":"additional","affiliation":[{"name":"Department of Haematology Fiona Stanley Hospital  Perth Western Australia Australia"},{"name":"Curtin Medical School Curtin University  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-3397","authenticated-orcid":false,"given":"Nicole Wong","family":"Doo","sequence":"additional","affiliation":[{"name":"Concord Clinical School, Faculty of Medicine and Health University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-3216","authenticated-orcid":false,"given":"David","family":"Routledge","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Peter MacCallum Cancer Centre &amp; The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Hocking","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Austin Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital Geelong, Barwon Health  Geelong Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-235X","authenticated-orcid":false,"given":"Jessica","family":"Heenan","sequence":"additional","affiliation":[{"name":"Department of Haematology, Holman Clinic Launceston General Hospital  Launceston Tasmania Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Horvath","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit Royal Adelaide Hospital  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chien","sequence":"additional","affiliation":[{"name":"Auckland Regional Blood and Cancer Service Auckland City Hospital  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E. P.","family":"Renwick","sequence":"additional","affiliation":[{"name":"Haematology Oncology Western Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-9022","authenticated-orcid":false,"given":"Georgia","family":"McCaughan","sequence":"additional","affiliation":[{"name":"Haematology Department, The Kinghorn Cancer Centre St Vincent's Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2357-1781","authenticated-orcid":false,"given":"Richard","family":"Eek","sequence":"additional","affiliation":[{"name":"Department of Haematology Border Medical Oncology  Albury New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8373-7517","authenticated-orcid":false,"given":"Douglas S.","family":"Lenton","sequence":"additional","affiliation":[{"name":"Department of Haematology Orange Hospital  Orange New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Monash Medical Centre  Melbourne Victoria Australia"},{"name":"Department of Cancer Services Latrobe Regional Health  Traralgon Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2729-2820","authenticated-orcid":false,"given":"Sher Gul","family":"Gazdar","sequence":"additional","affiliation":[{"name":"Australasian Leukaemia &amp; Lymphoma Group  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-6105","authenticated-orcid":false,"given":"Deepmala","family":"Mazumdar","sequence":"additional","affiliation":[{"name":"Australasian Leukaemia &amp; Lymphoma Group  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-4065","authenticated-orcid":false,"given":"Belinda","family":"Butcher","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences University of New South Wales  Sydney New South Wales Australia"},{"name":"WriteSource Medical Pty Ltd  Lane Cove New South Wales Australia"},{"name":"The University of Sydney Faculty of Medicine and Health, Sydney Pharmacy School  Camperdown New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-1198","authenticated-orcid":false,"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[{"name":"Faculty of Health, Medicine and Behavioural Sciences University of Queensland  Brisbane Queensland Australia"},{"name":"Department of Haematology Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Haematology St Vincent's Hospital Melbourne  Melbourne Victoria Australia"},{"name":"Faculty of Medicine, Dentistry and Health Sciences University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Australasian Leukaemia and Lymphoma Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"4","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld P","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant\u2010eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG\u2010HD7 trial","volume":"43","author":"Mai EK","year":"2025","journal-title":"J Clin Oncol"},{"issue":"29","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem\u2010cell transplantation in newly diagnosed multiple myeloma: a meta\u2010analysis","volume":"35","author":"McCarthy PL","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem\u2010cell transplantation for multiple myeloma","volume":"366","author":"Attal M","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem\u2010cell transplantation for multiple myeloma","volume":"366","author":"McCarthy PL","year":"2012","journal-title":"N Engl J Med"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High\u2010risk multiple myeloma: redefining genetic, clinical, and functional high\u2010risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees MJ","year":"2024","journal-title":"Am J Hematol"},{"issue":"10","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation\u2010eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open\u2010label, randomised, phase 2 trial","volume":"10","author":"Voorhees PM","year":"2023","journal-title":"Lancet Haematol"},{"issue":"8","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant\u2010eligible newly diagnosed multiple myeloma: long\u2010term follow\u2010up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau P","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros A","year":"2025","journal-title":"Blood"},{"issue":"10262","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once\u2010per\u2010week selinexor, bortezomib, and dexamethasone versus twice\u2010per\u2010week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open\u2010label, phase 3 trial","volume":"396","author":"Grosicki S","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1352281","article-title":"Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"14","author":"White D","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2019-124370","article-title":"Safety and efficacy of the combination of selinexor, lenalidomide and dexamethasone (SRd) in patients with newly diagnosed multiple myeloma","volume":"134","author":"White DJ","year":"2019","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-137154","article-title":"Once weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma: high\u2010risk cytogenetic risk planned subgroup analyses from the phase 3 Boston study","volume":"136","author":"Richard S","year":"2020","journal-title":"Blood"},{"issue":"18","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar SV","year":"2011","journal-title":"Blood"},{"issue":"9","key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie BGM","year":"2006","journal-title":"Leukemia"},{"issue":"24","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International myeloma society\/international myeloma working group consensus recommendations on the definition of high\u2010risk multiple myeloma","volume":"43","author":"Avet\u2010Loiseau H","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40487-021-00143-7","article-title":"Post\u2010transplant maintenance treatment options in multiple myeloma","volume":"9","author":"Karam D","year":"2021","journal-title":"Oncol Ther"},{"issue":"19","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo A","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/leu.2017.256","article-title":"Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation","volume":"32","author":"Chakraborty R","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00390-3","article-title":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma","volume":"11","author":"Baertsch MA","year":"2021","journal-title":"Blood Cancer J"},{"issue":"24","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON\u201065\/ GMMG\u2010HD4 trial","volume":"30","author":"Sonneveld P","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN evidence\u2010based guidelines for diagnosis, treatment and follow\u2010up of patients with multiple myeloma","volume":"22","author":"Dimopoulos MA","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"e_1_2_13_24_1","article-title":"Multiple myeloma, version 5.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Kumar SK","year":"2026","journal-title":"J Natl Compr Cancer Netw"},{"issue":"16","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2025.43.16_suppl.7501","article-title":"Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant\u2010eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial","volume":"43","author":"Moreau P","year":"2025","journal-title":"J Clin Oncol"},{"key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142913","article-title":"Phase III study of daratumumab\/rhuph20 (nsc\u2010 810307) + lenalidomide or lenalidomide as post\u2010autologous stem cell transplant maintenance therapyin patients with multiple myeloma (mm) using minimal residual disease todirect therapy duration (DRAMMATIC study): SWOG s1803","volume":"136","author":"Krishnan A","year":"2020","journal-title":"Blood"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000936220.68605.8b"},{"issue":"1","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 study of Teclistamab\u2010based induction regimens in patients with transplant\u2010eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG\u2010HD10\/DSMM\u2010XX (MajesTEC\u20105) trial","volume":"144","author":"Raab MS","year":"2024","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2024-205608","article-title":"Phase 3 study of Teclistamab (Tec) in combination with lenalidomide (Len) and Tec alone versus Len alone in newly diagnosed multiple myeloma (NDMM) As maintenance therapy following autologous stem cell transplantation (ASCT): safety run\u2010in (SRI) results from the Majestec\u20104\/EMN30 trial","volume":"144","author":"Zamagni E","year":"2024","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2025-101","article-title":"Iberdomide maintenance after autologous stem\u2010cell transplantation in newly diagnosed multiple myeloma: an update from the phase 2 EMN26 trial","volume":"146","author":"Donk NWCJ","year":"2025","journal-title":"Blood"},{"issue":"16","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066","article-title":"MagnetisMM\u20107: an open\u2010label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post\u2010transplant patients with newly diagnosed multiple myeloma","volume":"41","author":"Mateos Manteca MV","year":"2023","journal-title":"J Clin Oncol"},{"key":"e_1_2_13_32_1","unstructured":"van deDonkNWCJ SilzleT \u0160pi\u010dkaI TahriS NijhofIS FalconeAP et\u00a0al.Teclistamab +\/\u2212 Lenalidomide versus Len alone as maintenance therapy post\u2010transplant in Newly\u2010diagnosed Multiple Myeloma: Updated Safety Run\u2010In results from EMN30\/MajesTEC\u20104. EHA 2026 Congress; Stockholm2026."}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70851","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70851","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:47:34Z","timestamp":1790084854000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":31,"alternative-id":["10.1111\/bjh.70851"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70851","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"2026-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70851"}}